From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 14:16 (358 d 12:25 ago) – Posting: # 20924
Views: 3,076

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

Activity
 Admin contact
21,213 posts in 4,426 threads, 1,483 registered users;
online 15 (1 registered, 14 guests [including 9 identified bots]).
Forum time: Friday 02:41 UTC (Europe/Vienna)

Biostatistician. One who has neither the intellect for mathematics
nor the commitment for medicine but likes to dabble in both.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5